Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
171 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diarrhea - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Diarrhea - Pipeline Review, H1 2015', provides an overview of the Diarrhea's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diarrhea - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diarrhea and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diarrhea - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Diarrhea Overview 8 Therapeutics Development 9 Pipeline Products for Diarrhea - Overview 9 Pipeline Products for Diarrhea - Comparative Analysis 10 Diarrhea - Therapeutics under Development by Companies 11 Diarrhea - Therapeutics under Investigation by Universities/Institutes 15 Diarrhea - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Diarrhea - Products under Development by Companies 19 Diarrhea - Products under Investigation by Universities/Institutes 22 Diarrhea - Companies Involved in Therapeutics Development 23 A. Menarini Industrie Farmaceutiche Riunite Srl 23 Ache Laboratorios Farmaceuticos S/A 24 Actelion Ltd 25 Aegis Therapeutics, LLC 26 Assembly Biosciences, Inc. 27 Chiesi Farmaceutici SpA 28 Chongqing Zhifei Biological Products Co., Ltd. 29 Cosmo Pharmaceuticals S.p.A 30 Cubist Pharmaceuticals, Inc. 31 DesignMedix, Inc. 32 DiscoveryBiomed, Inc. 33 Furiex Pharmaceuticals, Inc. 34 GlycoVaxyn AG 35 GP Pharm, S.A. 36 Helsinn Healthcare S.A. 37 Intercept Pharmaceuticals, Inc. 38 Ipsen S.A. 39 Mucosis B.V. 40 Napo Pharmaceuticals, Inc. 41 Nippon Shinyaku Co., Ltd. 42 Novartis AG 43 Paratek Pharmaceuticals, Inc. 44 Pfizer Inc. 45 Prokarium Ltd. 46 Sanofi Pasteur SA 47 Scandinavian Biopharma Holding AB 48 Shire Plc 49 Sigmoid Pharma Limited 50 Summit Corporation plc 51 Syntiron LLC 52 Ventria Bioscience 53 Diarrhea - Therapeutics Assessment 54 Assessment by Monotherapy Products 54 Assessment by Target 55 Assessment by Mechanism of Action 58 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 64 ACE-527 - Drug Profile 64 ACE-920 - Drug Profile 66 ACH-04 - Drug Profile 67 AKT-10081 - Drug Profile 68 ASP-7147 - Drug Profile 69 cadazolid - Drug Profile 70 clostridium difficile vaccine - Drug Profile 71 crofelemer DR - Drug Profile 72 Diarrhea Vaccine - Drug Profile 74 diarrhea vaccine - Drug Profile 75 Drugs for CDAD - Drug Profile 76 elsiglutide - Drug Profile 77 eluxadoline - Drug Profile 78 Escherichia coli vaccine - Drug Profile 80 ETEC Adhesin-Based Vaccine - Drug Profile 81 Etvax - Drug Profile 82 fidaxomicin - Drug Profile 84 GVXNSD-133 - Drug Profile 87 helicobacter pylori vaccine [Hel-305] (multivalent) - Drug Profile 88 ibodutant - Drug Profile 89 infectious diarrhea [serotype H11] (H10407 and E24377A) vaccine - Drug Profile 90 INX-201 - Drug Profile 91 iOWH0-32 - Drug Profile 92 lanreotide acetate - Drug Profile 94 obeticholic acid - Drug Profile 96 octreotide - Drug Profile 99 octreotide acetate MAR - Drug Profile 100 Peptide for Enterocolitis and Infectious Diarrhea - Drug Profile 101 PF-06425090 - Drug Profile 102 prulifloxacin - Drug Profile 103 PZ-7475 - Drug Profile 105 RBX-2660 - Drug Profile 106 Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile 107 Recombinant Proteins for Infectious Diarrhea - Drug Profile 109 rifamycin - Drug Profile 110 Small Molecule to Inhibit EnaC and Activate CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 112 Small Molecules for Bacterial Infections - Drug Profile 113 Small Molecules for Diarrhea - Drug Profile 114 Small Molecules for Diarrhea - Drug Profile 115 Small Molecules to Inhibit CFTR for Secretory Diarrhea - Drug Profile 116 SMT-19969 - Drug Profile 117 surotomycin - Drug Profile 118 Tetracycline Derivatives for CDAD - Drug Profile 119 Typhetec - Drug Profile 120 Vaccine for Campylobacter Caused Diarrhea - Drug Profile 121 Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile 123 VEN-100 - Drug Profile 124 VP-20621 - Drug Profile 126 Yersinia pestis vaccine - Drug Profile 127 Diarrhea - Recent Pipeline Updates 128 Diarrhea - Dormant Projects 155 Diarrhea - Discontinued Products 157 Diarrhea - Product Development Milestones 158 Featured News & Press Releases 158 Appendix 166 Methodology 166 Coverage 166 Secondary Research 166 Primary Research 166 Expert Panel Validation 166 Contact Us 167 Disclaimer 167
List of Tables Number of Products under Development for Diarrhea, H1 2015 13 Number of Products under Development for Diarrhea - Comparative Analysis, H1 2015 14 Number of Products under Development by Companies, H1 2015 16 Number of Products under Development by Companies, H1 2015 (Contd..1) 17 Number of Products under Development by Companies, H1 2015 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H1 2015 19 Comparative Analysis by Late Stage Development, H1 2015 20 Comparative Analysis by Clinical Stage Development, H1 2015 21 Comparative Analysis by Early Stage Development, H1 2015 22 Products under Development by Companies, H1 2015 23 Products under Development by Companies, H1 2015 (Contd..1) 24 Products under Development by Companies, H1 2015 (Contd..2) 25 Products under Investigation by Universities/Institutes, H1 2015 26 Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 27 Diarrhea - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 28 Diarrhea - Pipeline by Actelion Ltd, H1 2015 29 Diarrhea - Pipeline by Aegis Therapeutics, LLC, H1 2015 30 Diarrhea - Pipeline by Assembly Biosciences, Inc., H1 2015 31 Diarrhea - Pipeline by Chiesi Farmaceutici SpA, H1 2015 32 Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2015 33 Diarrhea - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2015 34 Diarrhea - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 35 Diarrhea - Pipeline by DesignMedix, Inc., H1 2015 36 Diarrhea - Pipeline by DiscoveryBiomed, Inc., H1 2015 37 Diarrhea - Pipeline by Furiex Pharmaceuticals, Inc., H1 2015 38 Diarrhea - Pipeline by GlycoVaxyn AG, H1 2015 39 Diarrhea - Pipeline by GP Pharm, S.A., H1 2015 40 Diarrhea - Pipeline by Helsinn Healthcare S.A., H1 2015 41 Diarrhea - Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 42 Diarrhea - Pipeline by Ipsen S.A., H1 2015 43 Diarrhea - Pipeline by Mucosis B.V., H1 2015 44 Diarrhea - Pipeline by Napo Pharmaceuticals, Inc., H1 2015 45 Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 46 Diarrhea - Pipeline by Novartis AG, H1 2015 47 Diarrhea - Pipeline by Paratek Pharmaceuticals, Inc., H1 2015 48 Diarrhea - Pipeline by Pfizer Inc., H1 2015 49 Diarrhea - Pipeline by Prokarium Ltd., H1 2015 50 Diarrhea - Pipeline by Sanofi Pasteur SA, H1 2015 51 Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H1 2015 52 Diarrhea - Pipeline by Shire Plc, H1 2015 53 Diarrhea - Pipeline by Sigmoid Pharma Limited, H1 2015 54 Diarrhea - Pipeline by Summit Corporation plc, H1 2015 55 Diarrhea - Pipeline by Syntiron LLC, H1 2015 56 Diarrhea - Pipeline by Ventria Bioscience, H1 2015 57 Assessment by Monotherapy Products, H1 2015 58 Number of Products by Stage and Target, H1 2015 61 Number of Products by Stage and Mechanism of Action, H1 2015 63 Number of Products by Stage and Route of Administration, H1 2015 65 Number of Products by Stage and Molecule Type, H1 2015 67 Diarrhea Therapeutics - Recent Pipeline Updates, H1 2015 132 Diarrhea - Dormant Projects, H1 2015 159 Diarrhea - Dormant Projects (Contd..1), H1 2015 160 Diarrhea - Discontinued Products, H1 2015 161
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.